Detalhe da pesquisa
1.
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Br J Cancer
; 124(1): 191-206, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33257837
2.
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Breast Cancer Res Treat
; 157(2): 253-265, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27178332
3.
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Breast Cancer Res Treat
; 154(2): 225-37, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487496
4.
Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Breast Cancer Res Treat
; 150(3): 535-45, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25820519
5.
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Breast Cancer Res Treat
; 163(3): 639-640, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28439737
6.
Hormonal modulation of ESR1 mutant metastasis.
Oncogene
; 40(5): 997-1011, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33323970
7.
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Mol Cancer Ther
; 5(12): 3023-31, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17172405
8.
Correction to: Hormonal modulation of ESR1 mutant metastasis.
Oncogene
; 41(3): 460, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782721
9.
Developmental and stage-specific expression of Smad2 and Smad3 in rat testis.
J Androl
; 24(2): 192-200, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12634305